Rapid plaque clearance with anti-amyloid therapy for Alzheimer’s disease: in consideration of donanemab treatment duration from real-world cases
ABSTRACT To assess the possibility that individualized duration of donanemab treatment might enable early pausing of therapy, and to explore the possible utility of plasma P-tau217 as a biomarker for treatment response monitoring in real-time, two unrelated patients with early-stage Alzheimer’s disease were treated wit...